NCT01974713

Completed

Inflammatory Markers and Adverse Outcomes in Chronic Kidney ...

Institute of Kidney Lifescience Technologies Source

Compare

Other study identifiers

Sponsor study identifier

042010

Study Type

observational

Actual enrollment (reported)

2,530

Locations

0 countries

Sites

N/A

Timeline

Study Start

April 2010

Actual (reported)

Primary Completion

April 2016

Actual (reported)

Study Completion

July 2017

Actual (reported)

Brief Summary

Longitudinal cohort of patients with chronic kidney disease followed in 3 kidney centers in Ontario. The goal is to determine whether and how rates of renal disease progression are affected by inflammatory markers, FGF23 levels, and genetic polymorphisms

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 2,530 participants
Study completion date: July 2017
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
April 2010
Actual (reported)
First Submitted
October 28, 2013
Actual (reported)
First Posted
November 1, 2013
Actual (reported)
Primary Completion
April 2016
Actual (reported)
Study Completion
July 2017
Actual (reported)

Last Updated: September 1, 2017
Status Verified: August 2017
Last Update Submitted: August 31, 2017

Conditions

Chronic Kidney Disease

Keywords

CKD progressionInflammationFGF23Genetic biomarkers

Outcome Measures

Primary Outcomes (1)

Renal function at study censure
Estimated glomerular filtration rate after 3 years of follow-up in the study
3 years

Secondary Outcomes (1)

Dialysis-dependent renal failure
3 years

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients in chronic kidney disease clinic setting

You may qualify if:

Patients referred to a nephrologist for evaluation of CKD or those currently seen by a nephrologist, with eGFR less than 60 ml/min

Sponsors & Collaborators

Institute of Kidney Lifescience Technologies
Otherlead

Biospecimen

Retention: SAMPLES WITH DNA

serum

MeSH Terms

Conditions

Renal Insufficiency, ChronicInflammation

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Paul Y Tam, MD
Kidney Life Science Institute
PRINCIPAL INVESTIGATOR

Enrollment

2,530 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 3 Years
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 28, 2013

First Posted

November 1, 2013

Study Start

April 2010

Actual (reported)

NCT01036490

Exercise in Obese Diabetic Patients With Chronic Kidney Disease

Not ApplicableCompleted

NCT00938561

Evaluation of New Markers to Assess Kidney Function

Withdrawn

NCT01089829

Risk Factors for Foot Ulceration in the Chronic Kidney Disease (CKD) Population

Unknown

NCT01247311

Vitamin D and the Health of Blood Vessels in Kidney Disease

Not ApplicableCompleted

NCT01317173

Factors Related to the Progression of Chronic Kidney Disease

Unknown

NCT01364779

Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients

Completed

Patients that are erythropoietin treatment naive

Transplant patients with failing grafts requiring nephrologists follow-up

Patients currently not receiving RRT consenting to be in the study

Adults 18 years of age and older

You may not qualify if:

Functioning Organ transplant
Life expectancy less than 12 months
Patients currently receiving RRT or who will likely initiate RRT within 6 months
Patients unable or contraindicated to receive EPREX® as erythropoietin replacement therapy for the correction of anemia related to CKD

Contact the study team to confirm eligibility.

Primary Completion

April 2016

Actual (reported)

Study Completion

July 2017

Actual (reported)

Last Updated

September 1, 2017

Record last verified: 2017-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01974713
Data provider: ClinicalTrials.gov
Source updated: 2017-09-01
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:26:26 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record